![](https://d3ilqtpdwi981i.cloudfront.net/6IsJEAaJfv0mVhbJZPcbDXDGddQ=/425x550/smart/https://bepress-attached-resources.s3.amazonaws.com/uploads/21/0f/66/210f6631-3a00-4e87-b70a-11f392726f31/thumbnail_fec9bbe6-3c56-4af1-a195-79834609a12f.jpg)
PURPOSE: The purpose of this study was to test fluorine-19 (19F) cellular magnetic resonance (MRI) as a non-invasive imaging modality to track therapeutic cell migration as a surrogate marker of immunotherapeutic effectiveness.
MATERIALS AND METHODS: Human peripheral blood mononuclear cell- (PBMC)-derived antigen presenting cell (APC) were labeled with a 19F-perfluorocarbon (PFC) and/or activated with granulocyte macrophage colony-stimulating factor (GM-CSF). Viability, phenotype and cell lineage characterization preceded 19F cellular MRI of PFC
RESULTS: A high proportion of PBMC incorporated PFC without affecting viability, phenotype or cell lineage composition. PFC
CONCLUSION: 19F cellular MRI is a non-invasive imaging technique capable of detecting and quantifying in vivo cell migration in conjunction with an established APC-based immunotherapy model. 19F cellular MRI can function as a surrogate marker for assessing and improving upon the therapeutic benefit that this immunotherapy provides.
Available at: http://works.bepress.com/michael-rieder/14/
This article was first published in Diagnostic and Interventional Imaging at https://doi.org/10.1016/j.diii.2020.02.004.